Study analysis · Nature Medicine · 2025
Stem cells may have just slowed brain shrinkage in Alzheimer’s by nearly half — and it’s not what you think.
A special stem cell treatment helped people with early Alzheimer’s keep more of their brain and remember better for 9 months.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study tried a new treatment on a small group of people with early Alzheimer’s and compared them to others who got a fake treatment. It found that the real treatment might help a little with memory and brain shrinkage, but because so few people were in the study, we can’t be sure it’s really working — it might just be luck.
What’s the bottom line?
Scientists tested a special stem cell treatment called laromestrocel in people with early Alzheimer’s to see if it could stop their brains from shrinking and help them think better.
How strong is this study?
This study was done really well — people didn’t know if they got the real treatment or a placebo, and the doctors didn’t know either, which makes the results more trustworthy. But because only 49 people were in the whole study, it’s like testing a new candy on five kids and saying it’s the best candy ever — it’s a good start, but we need to try it on way more people to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
80 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=49)+4.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, the small sample size (n=49) and lack of statistical power for secondary outcomes limit the confidence in causal claims. The primary endpoint was safety, and efficacy signals are exploratory with p-values just below or above conventional thresholds, suggesting tentative rather than definitive causation.
Major COI
Major conflicts that significantly reduce study credibility
The study tested laromestrocel, a cell therapy product, with no explicit funding disclosure, but the product is clearly developed by a commercial entity, and the authors' affiliations suggest industry ties, indicating potential funder influence on study design and interpretation.
Conflict Details
Unknown: Study likely funded by entity developing laromestrocel, but no explicit funding source is stated.
No conflict of interest statement or funding disclosure is present in the provided text. Laromestrocel is a proprietary cell therapy product, and the study design, results, and language strongly suggest industry sponsorship. The absence of transparency raises significant concerns about potential bias in study conduct and reporting.
Key takeaways
- 01
After 9 months, treated patients had 48% less brain shrinkage and 62% less hippocampus shrinkage than placebo.
- 02
Their memory scores (MoCA) improved by 2.1 points, and a key blood marker of blood vessel damage (sTIE2) dropped.
- 03
These changes suggest the treatment may help preserve brain structure and thinking ability — important because brain shrinkage is linked to memory loss in Alzheimer’s.
Surprising findings
- The treatment’s effects on brain volume didn’t show up until after the last infusion — peaking at 39 weeks, not 16.Most therapies show immediate effects; here, the brain kept improving weeks after treatment stopped — suggesting long-lasting biological changes, not just temporary relief.
- A single dose (25M cells x1) showed nearly as much benefit as four doses in some measures — challenging the assumption that more is always better.The highest dose (100M x4) didn’t consistently outperform the lower dose — suggesting the body may respond to a threshold, not a dose-response curve.
Practical takeaways
If you or a loved one has early Alzheimer’s, ask your neurologist about clinical trials for laromestrocel or similar vascular-targeting stem cell therapies (search NCT05233774).
This is not an approved treatment yet — only available in research settings. Don’t pay for unregulated stem cell clinics claiming similar benefits.
medium confidenceSupport brain vascular health now — with exercise, blood pressure control, and omega-3s — since this study suggests vascular damage is a key driver of Alzheimer’s decline.
Lifestyle won’t replace future therapies, but it may delay progression and improve outcomes if stem cell treatments become available.
high confidenceWhy this study matters
Brain Atrophy Slowed by Nearly Half
Laromestrocel reduced whole-brain atrophy by 48.4% (P=0.005) and left hippocampal atrophy by 61.9% (P=0.021) over 39 weeks compared to placebo — measured via volumetric MRI in a randomized trial of 49 patients.
Brain shrinkage is one of the most visible signs of Alzheimer’s progression; slowing it by over half could mean preserving memory and independence longer — without drugs that cause brain bleeding.
No Brain Bleeding — Unlike Alzheimer’s Drugs
Despite testing in ApoE4 carriers (who have 3–5x higher risk), there were zero amyloid-related imaging abnormalities (ARIAs) — a major safety issue with FDA-approved drugs like lecanemab and aducanumab, which cause brain bleeds in up to 35% of patients.
Current Alzheimer’s drugs carry serious risks; this therapy appears safe even for the highest-risk group, making it a potential game-changer for combination treatments.
It Targets Blood Vessels, Not Just Plaques
The treatment reduced sTIE2 — a blood biomarker of damaged brain blood vessels — by up to 48% at week 16, suggesting it repairs the brain’s vascular system, not just amyloid plaques.
Most Alzheimer’s treatments focus on amyloid; this shows vascular health might be the missing link — and it’s something you can support with lifestyle too.
Cognitive Scores Improved — Even With Tiny Sample
MoCA scores improved by 2.1 points (P=0.015) in treated groups — enough to move someone from 'mild impairment' to 'normal cognition' on standard scales, despite only 49 patients.
A 2-point MoCA gain is clinically meaningful — it could mean remembering names, managing meds, or driving again — something families desperately want.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a special stem cell treatment called laromestrocel in people with early Alzheimer’s to see if it could stop their brains from shrinking and help them think better.
Research results
After 9 months, treated patients had 48% less brain shrinkage and 62% less hippocampus shrinkage than placebo. Their memory scores (MoCA) improved by 2.1 points, and a key blood marker of blood vessel damage (sTIE2) dropped.
What this means - more context
These changes suggest the treatment may help preserve brain structure and thinking ability — important because brain shrinkage is linked to memory loss in Alzheimer’s.
This phase 2a trial evaluated the safety and efficacy of laromestrocel, an allogeneic mesenchymal stem cell therapy, in slowing cognitive decline and brain atrophy in mild Alzheimer’s disease.
Laromestrocel was safe and well tolerated in mild Alzheimer’s patients, with no serious adverse events or ARIAs. It significantly slowed whole-brain atrophy by 48.4% and left hippocampal atrophy by 61.9% over 39 weeks compared to placebo, correlated with cognitive stability. MoCA scores improved significantly, and sTIE2 (a vascular dysfunction biomarker) decreased, suggesting vascular target engagement.
Methods Used
Randomized, double-blind, placebo-controlled phase 2a trial with 49 mild Alzheimer’s patients assigned 1:1:1:1 to placebo or laromestrocel (25 or 100 million cells, 1 or 4 monthly IV infusions). Primary endpoint: safety (SAEs within 4 weeks of infusion). Secondary/Exploratory endpoints: cognitive scores (MoCA, MMSE-2), brain volumetry (vMRI), DTI, and serum biomarkers (sTIE2) over 39 weeks.
Main Finding
Laromestrocel significantly slowed whole-brain atrophy by 48.4% (P=0.005) and left hippocampal atrophy by 61.9% (P=0.021) over 39 weeks versus placebo, with a 2.1-point MoCA improvement (P=0.015) and reduced sTIE2 levels, indicating vascular target engagement and neuroprotection.
Confidence Level
Moderate — small sample size (n=49), short duration (39 weeks), and composite endpoint (CADS) not validated; however, robust methodology (RCT, blinding, MRI biomarkers, pre-registered protocol) supports preliminary efficacy signals.
Study Flags
Red Flags
- •Small sample size (n=49)
- •Short follow-up (39 weeks)
- •Composite endpoint (CADS) not previously validated
Surprising Findings
The treatment’s effects on brain volume didn’t show up until after the last infusion — peaking at 39 weeks, not 16.
Most therapies show immediate effects; here, the brain kept improving weeks after treatment stopped — suggesting long-lasting biological changes, not just temporary relief.
Practical Takeaways
If you or a loved one has early Alzheimer’s, ask your neurologist about clinical trials for laromestrocel or similar vascular-targeting stem cell therapies (search NCT05233774).
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study tried a new treatment on a small group of people with early Alzheimer’s and compared them to others who got a fake treatment. It found that the real treatment might help a little with memory and brain shrinkage, but because so few people were in the study, we can’t be sure it’s really working — it might just be luck.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Use of intention-to-treat and modified ITT analysis
- Pre-specified primary and secondary endpoints
Weaknesses
- Small sample size leading to low statistical power (36% power for primary efficacy outcome)
- Multiple comparisons without adjustment for multiplicity
- Secondary endpoints were exploratory and not pre-specified as primary
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested a special stem cell treatment called laromestrocel in people with early Alzheimer’s to see if it could stop their brains from shrinking and help them think better.
Research results
After 9 months, treated patients had 48% less brain shrinkage and 62% less hippocampus shrinkage than placebo. Their memory scores (MoCA) improved by 2.1 points, and a key blood marker of blood vessel damage (sTIE2) dropped.
What this means - more context
These changes suggest the treatment may help preserve brain structure and thinking ability — important because brain shrinkage is linked to memory loss in Alzheimer’s.
This phase 2a trial evaluated the safety and efficacy of laromestrocel, an allogeneic mesenchymal stem cell therapy, in slowing cognitive decline and brain atrophy in mild Alzheimer’s disease.
Laromestrocel was safe and well tolerated in mild Alzheimer’s patients, with no serious adverse events or ARIAs. It significantly slowed whole-brain atrophy by 48.4% and left hippocampal atrophy by 61.9% over 39 weeks compared to placebo, correlated with cognitive stability. MoCA scores improved significantly, and sTIE2 (a vascular dysfunction biomarker) decreased, suggesting vascular target engagement.
Methods Used
Randomized, double-blind, placebo-controlled phase 2a trial with 49 mild Alzheimer’s patients assigned 1:1:1:1 to placebo or laromestrocel (25 or 100 million cells, 1 or 4 monthly IV infusions). Primary endpoint: safety (SAEs within 4 weeks of infusion). Secondary/Exploratory endpoints: cognitive scores (MoCA, MMSE-2), brain volumetry (vMRI), DTI, and serum biomarkers (sTIE2) over 39 weeks.
Main Finding
Laromestrocel significantly slowed whole-brain atrophy by 48.4% (P=0.005) and left hippocampal atrophy by 61.9% (P=0.021) over 39 weeks versus placebo, with a 2.1-point MoCA improvement (P=0.015) and reduced sTIE2 levels, indicating vascular target engagement and neuroprotection.
Confidence Level
Moderate — small sample size (n=49), short duration (39 weeks), and composite endpoint (CADS) not validated; however, robust methodology (RCT, blinding, MRI biomarkers, pre-registered protocol) supports preliminary efficacy signals.
Study Flags
Red Flags
- •Small sample size (n=49)
- •Short follow-up (39 weeks)
- •Composite endpoint (CADS) not previously validated
Surprising Findings
The treatment’s effects on brain volume didn’t show up until after the last infusion — peaking at 39 weeks, not 16.
Most therapies show immediate effects; here, the brain kept improving weeks after treatment stopped — suggesting long-lasting biological changes, not just temporary relief.
Practical Takeaways
If you or a loved one has early Alzheimer’s, ask your neurologist about clinical trials for laromestrocel or similar vascular-targeting stem cell therapies (search NCT05233774).
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study tried a new treatment on a small group of people with early Alzheimer’s and compared them to others who got a fake treatment. It found that the real treatment might help a little with memory and brain shrinkage, but because so few people were in the study, we can’t be sure it’s really working — it might just be luck.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Use of intention-to-treat and modified ITT analysis
- Pre-specified primary and secondary endpoints
Weaknesses
- Small sample size leading to low statistical power (36% power for primary efficacy outcome)
- Multiple comparisons without adjustment for multiplicity
- Secondary endpoints were exploratory and not pre-specified as primary
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was done really well — people didn’t know if they got the real treatment or a placebo, and the doctors didn’t know either, which makes the results more trustworthy. But because only 49 people were in the whole study, it’s like testing a new candy on five kids and saying it’s the best candy ever — it’s a good start, but we need to try it on way more people to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
80 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=49)+4.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, the small sample size (n=49) and lack of statistical power for secondary outcomes limit the confidence in causal claims. The primary endpoint was safety, and efficacy signals are exploratory with p-values just below or above conventional thresholds, suggesting tentative rather than definitive causation.
Major COI
Major conflicts that significantly reduce study credibility
The study tested laromestrocel, a cell therapy product, with no explicit funding disclosure, but the product is clearly developed by a commercial entity, and the authors' affiliations suggest industry ties, indicating potential funder influence on study design and interpretation.
Conflict Details
Unknown: Study likely funded by entity developing laromestrocel, but no explicit funding source is stated.
No conflict of interest statement or funding disclosure is present in the provided text. Laromestrocel is a proprietary cell therapy product, and the study design, results, and language strongly suggest industry sponsorship. The absence of transparency raises significant concerns about potential bias in study conduct and reporting.